t(1;18)(q10;q10)
Adriana Zamecnikova
Kuwait Cancer Control Center, Dep of Hematology, Laboratory of Cancer Genetics, Kuwait (AZ)

Published in Atlas Database: March 2013
Online updated version : http://AtlasGeneticsOncology.org/Anomalies/t0118q10q10ID1254.html
DOI: 10.4267/2042/51540

This article is an update of:

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2013 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Clinics and pathology

Disease
Only 5 cases of hematological malignancy with der(1;18) are reported in the literature. Four cases of chronic myeloproliferative disorders (CMD) (one case with myelodysplastic syndrome, one patient with CMD, unclassifiable, one with essential thrombocytemia (ET) coexistent with the JAK2 V617F mutation, one idiopathic myelofibrosis (IMF)) and one patient was diagnosed with multiple myeloma.

Phenotype/cell stem origin
Unknown, but may involve a myeloid progenitor cell as both reported cases can be grouped under myeloid malignancy.

Clinics
The first case was a 23-year old male who presented as myelodysplastic syndrome that rapidly progressed to acute myeloid leukemia, and died of neutropenic sepsis at induction phase.
The second case was a 65-year-old female diagnosed as chronic myeloproliferative disorder, unclassifiable, and run a chronic stable clinical course for years. She however suffered from recurrent pyogenic cutaneous infection. The patient with essential thrombocythemia was a 75-year-old woman receiving ranimustine therapy. The case with IMF was a male with a history of polycythemia vera (PV) and normal karyotype at diagnosis.

**Prognosis**

Owing to the small number of cases reported, the prognostic implication of der(1;18)(q10;q10) remains to be defined. The clinical outcome of the two reported cases with detailed clinical course were markedly different, with one having rapid downhill course and short survival whereas the other one having chronic disease.

**Cytogenetics**

**Cytogenetics morphological**

Found in the unbalanced form -18, + der(1;18), with trisomy for 1q and monosomy for 18p.

**Additional anomalies**

Sole abnormality in 3 of 4 patients with chronic myeloproliferative disorders; +22 reported as additional abnormality in a post-polycyemic myelofibrosis patient. Patient with multiple myeloma had a complex karyotype with der(8)(t;8;11)(q24;q13)ins(8;22)(q24;q11q11) and numerical changes.

**Genes involved and proteins**

**Note**

Genes involved are unknown. Mechanistically, either trisomy 1q or monosomy 18p that results from the unbalanced translocation may potentially contribute to leukemogenesis. Whole arm chromosome translocations resulting in trisomy of the long arm of chromosome chromosome 1 have been identified with several partner chromosomes including chromosomes 7, 9, 13, 15, 16 and Y in BCR-ABL-negative myeloproliferative neoplasms (MPN). While the underlying mechanisms for these chromosomal alterations are unclear, it is likely that chromosomes with large constitutive heterochromatin bands such as chromosome 1 may be at risk of centromeric instability and be predisposed to centromeric fusion with other chromosomes. These observations suggest that a gene dosage effect of certain chromosome 1q regions, analogous to numerical aberrations may be involved in disease pathogenesis. Additionally, deletion of 18p may also contribute to clonal proliferation through loss of putative tumor suppressor genes, analogous to numerical aberrations and deletions associated with both chronic and advanced phases of MPN. In support of this contention, deletions on chromosome 18p as a result of der(18)(t;9;18)(p13;p11) and der(9;18)(p10;q10) associated with the JAK2 V617F mutation have been described with phenotypes of transitional PV and IMF, suggesting that 18p deletion may be associated with myeloproliferative disorders showing a high propensity to transformation. While the association of derivative (1;18) with JAK2 V617F still remain elusive, it is possible that that patients having this chromosome abnormality together with the JAK2 V617F mutation may belong to the subgroup of patients with highly proliferative phenotype of MPN which potentially transforms into acute myeloid leukemia.

**Result of the chromosomal anomaly**

**Hybrid gene**

This abnormality yields the net result of an extra / third copy of chromosome 1q and a deletion of chromosome 18p.

**References**


Wan TS, Ma SK, Au WY, Chan LC. Derivative (1;18)(q10;q10): a recurrent and novel unbalanced translocation involving 1q in myeloid disorders. Cancer Genet Cytogenet. 2001 Jul 1;128(1):35-8

Larsen TS, Hasselbalch HC, Pallisgaard N et al. A der(18)(t;9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycytemic myelofibrosis. Cancer Genet Cytogenet. 2007 Jan 15;172(2):107-12

Gabrea A, Martelli ML, Qi Y, Roschke A et al.. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. Genes Chromosomes Cancer. 2008 Jul;47(7):573-90


This article should be referenced as such: